Related references
Note: Only part of the references are listed.Risk Stratification Based on Chronic Liver Failure Consortium Acute Decompensation Score in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding
Yong Lv et al.
HEPATOLOGY (2021)
Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore
Enora Laas et al.
BRITISH JOURNAL OF CANCER (2021)
Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy
Olga Kantor et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Development and Validation of a Nomogram for Individually Predicting Pathologic Complete Remission After Preoperative Chemotherapy in Chinese Breast Cancer: A Population-Based Study
Niuniu Hou et al.
CLINICAL BREAST CANCER (2020)
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
Evandro de Azambuja et al.
ESMO OPEN (2020)
Validation of Residual Proliferative Cancer Burden as a Predictor ofLong-TermOutcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer
Federica Miglietta et al.
ONCOLOGIST (2020)
Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis
Jinluan Li et al.
ESMO OPEN (2020)
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Jinchul Kim et al.
ESMO OPEN (2020)
Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer
Tatiana M. Prowell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
Tessa G. Steenbruggen et al.
CLINICAL CANCER RESEARCH (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
S. J. Luen et al.
ANNALS OF ONCOLOGY (2019)
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
Qiuhe Wang et al.
JOURNAL OF HEPATOLOGY (2019)
Validation of the CPS plus EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China
Ling Xu et al.
BREAST (2018)
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma
Anne-Sophie Hamy et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Jeffrey I. Campbell et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy
Jacques Raphael et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
Misun Choi et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
Abram Recht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis
Kristine R. Broglio et al.
JAMA ONCOLOGY (2016)
The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy Incorporation of Prognostic Biologic Factors Into Staging After Treatment
Elizabeth A. Mittendorf et al.
JAMA ONCOLOGY (2016)
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Sarah S. Mougalian et al.
CANCER (2015)
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
Elena Provenzano et al.
MODERN PATHOLOGY (2015)
Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Tarek M. Abdel-Fatah et al.
CLINICAL CANCER RESEARCH (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer
Aditya Bardia et al.
CLINICAL CANCER RESEARCH (2013)
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
Paul Blanche et al.
STATISTICS IN MEDICINE (2013)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
Bhumsuk Keam et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
Elizabeth A. Mittendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A simple system for grading the response of breast cancer to neoadjuvant chemotherapy
S. Rodenhuis et al.
ANNALS OF ONCOLOGY (2010)
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2010)
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
V. Guarneri et al.
ANNALS OF ONCOLOGY (2009)
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
M. Colleoni et al.
ANNALS OF ONCOLOGY (2009)
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
Jacqueline S. Jeruss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Decision curve analysis: A novel method for evaluating prediction models
Andrew J. Vickers et al.
MEDICAL DECISION MAKING (2006)
Size of residual lymph node metastasis after neoadjuvant chemotherapy in locally advanced breast cancer patients is prognostic
N Klauber-DeMore et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
R Rouzier et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
American joint committee on cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome
LA Carey et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
RL Camp et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
